Hurais Malik

Hurais Malik

Auto-generated profile, based on publicly available information

Hurais Malik

Department of Medicine, Fazaia Ruth Pfau Medical College, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Journal of Anesthesia, Analgesia and Critical Care
Verified
Journal Article
Open access
PDF file
MHMuhammad Hudaib
Muhammad Hudaib
HMHurais Malik
Hurais Malik
SZSyeda Javeria Zakir
Syeda Javeria Zakir
SRSamra Rabbani
Samra Rabbani
DGDhanushan Gnanendran
Dhanushan Gnanendran
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
Background: Propofol has been the gold standard for anesthesia induction and maintenance due to its rapid onset and favorable pharmacokinetic properties. However, the search for alternative agents with improved safety and efficacy has led to the emergence of ciprofol (HSK3486), a structural analog of propofol. This systematic review and meta-analysis aim to comprehensively assess the safety and efficacy of ciprofol compared to propofol for anesthesia induction and maintenance in adult patients undergoing surgical procedures. Methods: This study included only double-arm RCTs in which participants were aged eighteen or older undergoing surgery. For the statistical analysis of the extracted data, we employed RevMan 5.4.1. Results: Ciprofol demonstrated a promising trend of higher anesthesiologists’ satisfaction during the induction phase (MD 0.14, 95%, CI − 0.28 to 0.56, p = 0.51), whereas Propofol was favored during maintenance. Propofol also exhibited advantages with a shorter time to successful anesthesia induction (MD 0.08 min, 95% CI 0.00 to 0.15, p = 0.04), and quicker attainment of full alertness (MD 0.11 min, 95% CI − 1.29 to 1.52, p = 0.87), suggesting its efficiency in clinical practice. Importantly, there were no significant disparities in the success rate of anesthesia. Conclusion: Both ciprofol and propofol demonstrate comparable efficacy and safety for anesthesia induction and maintenance in adult patients undergoing surgery. While propofol provides a faster onset of induction, ciprofol exhibits advantages in terms of pain management. Clinicians should consider these findings when selecting anesthetic agents, and tailoring choices to individual patient needs and clinical scenarios.

1 January 2024 in Environmental Health Insights
Verified
Journal Article
Open access
YSYumna Shariff
Yumna Shariff
MMMuneeba Mushtaq
Muneeba Mushtaq
SSSyed Muhammad Abdullah Shah
Syed Muhammad Abdullah Shah
HMHurais Malik
Hurais Malik
MAMuhammad Abdullah
Muhammad Abdullah
MEMohammed Mahmmoud Fadelallah Eljack
Mohammed Mahmmoud Fadelallah Eljack
Climate change represents an unprecedented global public health crisis with extensive and profound implications. The Lancet Commission identified it as the foremost health challenge of the 21st century. In 2015, air pollution alone caused approximately 9 million premature deaths worldwide. Climate change also exacerbates extreme weather events, displacement, mental health disorders, disease vectors, food insecurity, and malnutrition, particularly impacting vulnerable developing countries like Pakistan due to its agricultural reliance, diverse topography, and limited resources. This study assesses Pakistani medical students’ perceptions of climate change’s health impacts. Conducted in February 2024, a cross-sectional survey of 632 students using a standardized questionnaire was employed via online Google Forms. The questionnaire was validated and an Exploratory Factor Analysis identified seven subscales of environmental health consciousness. The mean participant age was 21.17 years, with a balanced gender distribution. Students showed high environmental health consciousness (Mean = 35.6, SD = 5.2), with 88% attributing climate change to human activities and 89.1% anticipating serious future health impacts. Significant concerns included air quality-related illness (91%), water-availability illness (86%), healthcare disruption (85%), cold-related illness (83%), and flooding-related displacement (87%). Psychological impacts were acknowledged by 68%. Household income, age, and gender were significant predictors. These results highlight the need for integrating climate change and health education into medical curricula to prepare future healthcare providers.

6 December 2024 in Medicine
Verified
Journal Article
Open access
MWMaryam Abdul Mbbs Wahid
Maryam Abdul Mbbs Wahid
MKMuhammad Taimur Mbbs Khan
Muhammad Taimur Mbbs Khan
JHJawairya Muhammad Mbbs Hussain
Jawairya Muhammad Mbbs Hussain
HMHurais Mbbs Malik
Hurais Mbbs Malik
SUShahood Ahmed Mbbs Umar
Shahood Ahmed Mbbs Umar
MEMohammed Mahmmoud Fadelallah Eljack
Mohammed Mahmmoud Fadelallah Eljack
Gliomas are tumors arising in the central nervous system, frequently associated with Class I mutations and BRAF fusions. These mutations are adverse prognostic factors in juvenile gliomas, leading to high rates of recurrence and poor response to current treatments. The blood-brain barrier and the heterogeneity of gliomas complicate the development of a single treatment strategy for all cases. This review aims to evaluate the efficacy and safety of combination therapies, particularly Dabrafenib and Trametinib, in pediatric gliomas with BRAF V600 mutations and discusses their potential in improving clinical outcomes. A review of recent clinical trials was conducted to assess the impact of targeted therapies, especially the combination of Dabrafenib and Trametinib, on glioma treatment outcomes. Additional therapies are also explored. Combination therapy with Dabrafenib, a BRAF kinase inhibitor, and Trametinib, a MEK inhibitor, has shown significant improvement in overall survival and progression-free survival for pediatric patients with BRAF V600-mutant gliomas. Recent clinical data from 2023 demonstrated enhanced tumor control, reduced relapse rates, and improved safety profiles compared to conventional therapies. Dabrafenib and Trametinib offer a promising targeted therapy for juvenile gliomas with BRAF V600 mutations, with better survival outcomes and manageable safety profiles. However, challenges remain in managing side effects such as fever, headache, lethargy, and rash. Further research into resistance mechanisms and long-term effects is necessary to optimize treatment strategies. Other therapies, such as everolimus and Selumetinib, also show potential and warrant further investigation.

2 October 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SASyed Hassan Ahmed
Syed Hassan Ahmed
MSMariam Shahabi
Mariam Shahabi
HMHurais Malik
Hurais Malik
SAShiza Abid
Shiza Abid
Md. Al HasibuzzamanMd. Al Hasibuzzaman
Md. Al Hasibuzzaman
An abstract is unavailable. This article is available as a PDF only.

17 January 2025 in Medicine
Verified
Journal Article
Open access
HMHurais Mbbs Malik
Hurais Mbbs Malik
MDMuhammad Fazal Ud Mbbs Din
Muhammad Fazal Ud Mbbs Din
MFMuhammad Aqib Faizan
Muhammad Aqib Faizan
TRTooba Rehman
Tooba Rehman
MHMuhammad Mbbs Hudaib
Muhammad Mbbs Hudaib
PBPratik Bhattarai
Pratik Bhattarai
Background: Soil-transmitted helminthiasis remains a daunting challenge to global health, exerting its greatest toll on resource-limited regions of the world. A dual drug approach using the co-administration of ivermectin and albendazole has shown promising results in comparison to the traditional monotherapy strategy. In light of this, a systematic review and meta-analysis of randomized controlled trials was conducted. Methods: Several electronic databases including PubMed, Cochrane Central, Google Scholar, and Embase were explored to search for relevant studies from inception to September 2023. The Cochrane Risk of Bias Tool for Randomized Controlled Studies was utilized to evaluate the quality of studies. Results: A total of 8 randomized controlled trials, reporting 10 patient populations, were included. The treatment of trichuriasis significantly favored the dual therapy regimen of ivermectin–albendazole over albendazole-only monotherapy (risk ratio [RR]: 2.86; 95% confidence interval [CI]: 1.66–4.93; P = .0002), with no significant differences observed for ascariasis and hookworm. The treatment of trichuriasis and hookworm significantly favored the dual therapy regimen of ivermectin–albendazole over ivermectin-only monotherapy (RR: 1.86; 95% CI: 1.56–2.21; P < .00001 and RR: 2.31; 95% CI: 1.23–4.31; P = .009, respectively). There were no statistically significant differences between dual therapy and monotherapy in terms of adverse effects. Conclusion: These findings highlight the nuanced effectiveness of combined therapy specific to certain helminth types, in addition to their comparable safety profiles, thereby providing pivotal insights that contribute to the evolving landscape of soil-transmitted helminth treatment strategies.

24 April 2024 in Journal of Anesthesia, Analgesia and Critical Care
Verified
Journal Article
Open access
PDF file
MHMuhammad Hudaib
Muhammad Hudaib
HMHurais Malik
Hurais Malik
SZSyeda Javeria Zakir
Syeda Javeria Zakir
SRSamra Rabbani
Samra Rabbani
DGDhanushan Gnanendran
Dhanushan Gnanendran
Giustino VarrassiGiustino Varrassi
Giustino Varrassi